undamentalytics Newsletter
Sign in

Alterity Therapeutics LTD cash flow statement

In fiscal 2018, Alterity Therapeutics LTD's operations generated −$4.8m of cash; it spent $48,380 on capital projects, leaving free cash flow of −$4.9m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Jun 20162017Jun 20172018Jun 2018
Cash from operations−5,407−4,425−4,842
Depreciation and amortisation171617
Capital spending22148
Free cash flow−5,409−4,446−4,890

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alterity Therapeutics LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alterity Therapeutics LTD.